[
  {
    "ts": null,
    "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
    "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
    "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762809600,
      "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
      "id": 137415864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
      "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396"
    }
  },
  {
    "ts": null,
    "headline": "Top 3 Dividend Stocks To Enhance Your Portfolio",
    "summary": "As the U.S. stock market shows signs of optimism with major indexes rebounding on hopes for a resolution to the government shutdown, investors are keenly observing opportunities to strengthen their portfolios. In such an environment, dividend stocks can offer a compelling mix of income and stability, making them an attractive option for those looking to enhance their investment strategy amidst ongoing economic developments.",
    "url": "https://finnhub.io/api/news?id=e767e8e9086578e609e47437f7c06d8a736fe720fa8dde435097295a61329288",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762795929,
      "headline": "Top 3 Dividend Stocks To Enhance Your Portfolio",
      "id": 137396621,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As the U.S. stock market shows signs of optimism with major indexes rebounding on hopes for a resolution to the government shutdown, investors are keenly observing opportunities to strengthen their portfolios. In such an environment, dividend stocks can offer a compelling mix of income and stability, making them an attractive option for those looking to enhance their investment strategy amidst ongoing economic developments.",
      "url": "https://finnhub.io/api/news?id=e767e8e9086578e609e47437f7c06d8a736fe720fa8dde435097295a61329288"
    }
  },
  {
    "ts": null,
    "headline": "Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?",
    "summary": "Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.",
    "url": "https://finnhub.io/api/news?id=ba607b02c5b7a18fdb3ab8ddbc16e86661c5ac6e3241af8f621539511d66e5f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762786080,
      "headline": "Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?",
      "id": 137396622,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.",
      "url": "https://finnhub.io/api/news?id=ba607b02c5b7a18fdb3ab8ddbc16e86661c5ac6e3241af8f621539511d66e5f8"
    }
  },
  {
    "ts": null,
    "headline": "AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer",
    "summary": "OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl",
    "url": "https://finnhub.io/api/news?id=630d3f4cb3803e0f098ae99e88aacf075e4eb4d3fdbc73f4e209d82e795accdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762782900,
      "headline": "AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer",
      "id": 137394958,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl",
      "url": "https://finnhub.io/api/news?id=630d3f4cb3803e0f098ae99e88aacf075e4eb4d3fdbc73f4e209d82e795accdd"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
    "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
    "url": "https://finnhub.io/api/news?id=cc7a183f7fe3cd4d840142981899394dab95a0a36ec28cb1312070c9882682ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762782840,
      "headline": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
      "id": 137394959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
      "url": "https://finnhub.io/api/news?id=cc7a183f7fe3cd4d840142981899394dab95a0a36ec28cb1312070c9882682ea"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript",
    "summary": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call November 9, 2025 7:01 PM ESTCompany ParticipantsPeter Dannenbaum - Vice President of Investor...",
    "url": "https://finnhub.io/api/news?id=f15ebf9c42e1c3621b018db8bd50cc9d8b231e235f8500260585494e811719f5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762777296,
      "headline": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript",
      "id": 137396151,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call November 9, 2025 7:01 PM ESTCompany ParticipantsPeter Dannenbaum - Vice President of Investor...",
      "url": "https://finnhub.io/api/news?id=f15ebf9c42e1c3621b018db8bd50cc9d8b231e235f8500260585494e811719f5"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow",
    "summary": "2025-11-10. The following slide deck was published by Merck & Co., Inc.",
    "url": "https://finnhub.io/api/news?id=ab1b99be7e1f344616d3249de66d190b7b6d71a0474efedf36ece334b5937643",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762736474,
      "headline": "Merck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow",
      "id": 137392215,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "2025-11-10. The following slide deck was published by Merck & Co., Inc.",
      "url": "https://finnhub.io/api/news?id=ab1b99be7e1f344616d3249de66d190b7b6d71a0474efedf36ece334b5937643"
    }
  }
]